Chronicles of cancer: A history of mammography

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

RCC patients with brain-only metastases may benefit from cytoreductive nephrectomy

Daugherty M et al. Urol Oncol. 2018 Dec 5.doi: 10.1016/j.urolonc.2018.10.021

Publish date:: December 24, 2018

Key clinical point: Renal cell carcinoma patients with brain-only metastases may experience durable long-term survival following cytoreductive nephrectomy.

Major finding: Two-year survival was 52% and 14%, respectively, for patients with brain-only metastases who did and did not undergo the procedure.

Study details: A retrospective analysis of Surveillance, Epidemiology, and End Results (SEER) Program data including 6,403 patients with metastatic RCC and complete data on sites of metastasis.

Disclosures: Dr. Bratslavsky and coauthors listed no disclosures related to their research.

Read the article here.

Citation:

Daugherty M et al. Urol Oncol. 2018 Dec 5.doi: 10.1016/j.urolonc.2018.10.021.

This Week's Must Reads

Elotuzumab-based therapy may benefit post-transplant response in multiple myeloma,

BALL score predicts benefit from ibrutinib therapy in relapsed/refractory CLL patients,

Many children with COVID-19 present without classic symptoms,

System provides ‘faster, less invasive’ method for breast cancer detection,

Posaconazole prophylaxis was effective in children with ALL undergoing chemotherapy,

Must Reads in Renal Cell Carcinoma

Study: Immune checkpoint inhibitors don’t increase risk of death in cancer patients with COVID-19,

Robotic renal surgery bests open partial nephrectomy,

CCC19, other registries help define COVID-19/cancer landscape,

Study supports changing classification of renal cell carcinoma,

Personalized cancer vaccine may enhance checkpoint inhibitor activity,